Haemostatix
Industry Sector
Biotechnology
Deal Type
Early Stage
Date
2005 - 2016
Haemostatix developed first-in-class clotting agents for the treatment of bleeding or 'haemostasis'.
How did we help?
We were an early investor in the business, helping it develop its early technology, secure grants and get ready for clinical trials.
Result
In May 2016, Haemostatix was sold to Ergomed plc, which is listed on AIM.